Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IGC |
---|---|---|
09:32 ET | 12401 | 0.36 |
09:33 ET | 113 | 0.3526 |
09:35 ET | 100 | 0.3598 |
09:37 ET | 250 | 0.3598 |
09:42 ET | 100 | 0.3597 |
09:46 ET | 3100 | 0.3597 |
09:48 ET | 1076 | 0.3573 |
09:50 ET | 884 | 0.3597 |
09:51 ET | 100 | 0.355 |
09:53 ET | 750 | 0.355 |
10:04 ET | 116 | 0.3586 |
10:06 ET | 218 | 0.35001 |
10:09 ET | 450 | 0.3586 |
10:11 ET | 150 | 0.3586 |
10:13 ET | 100 | 0.3586 |
10:15 ET | 407 | 0.3585 |
10:18 ET | 300 | 0.3586 |
10:22 ET | 1050 | 0.3585 |
10:26 ET | 139 | 0.358499 |
10:27 ET | 600 | 0.3585 |
10:29 ET | 130 | 0.3543 |
10:31 ET | 100 | 0.3585 |
10:33 ET | 100 | 0.3584 |
10:36 ET | 200 | 0.3543 |
10:40 ET | 100 | 0.3584 |
10:45 ET | 131 | 0.3584 |
10:47 ET | 100 | 0.3584 |
10:56 ET | 200 | 0.3582 |
10:58 ET | 600 | 0.3583 |
11:00 ET | 300 | 0.3542 |
11:02 ET | 100 | 0.3583 |
11:03 ET | 1000 | 0.3543 |
11:16 ET | 400 | 0.3582 |
11:18 ET | 213 | 0.3503 |
11:27 ET | 100 | 0.3581 |
11:36 ET | 200 | 0.3579 |
11:39 ET | 100 | 0.358 |
11:41 ET | 270 | 0.356592 |
11:43 ET | 300 | 0.358 |
11:45 ET | 309 | 0.3542 |
11:48 ET | 100 | 0.351471 |
11:54 ET | 100 | 0.3579 |
11:56 ET | 368 | 0.3541 |
11:59 ET | 100 | 0.3579 |
12:01 ET | 591 | 0.3542 |
12:03 ET | 235 | 0.3542 |
12:06 ET | 291 | 0.3578 |
12:10 ET | 20188 | 0.3505 |
12:12 ET | 3254 | 0.351 |
12:14 ET | 11800 | 0.3578 |
12:26 ET | 100 | 0.3577 |
12:28 ET | 3100 | 0.3541 |
12:30 ET | 2300 | 0.354101 |
12:33 ET | 100 | 0.3577 |
12:37 ET | 100 | 0.3576 |
12:39 ET | 200 | 0.3506 |
12:42 ET | 100 | 0.351 |
12:44 ET | 100 | 0.3576 |
12:48 ET | 4626 | 0.3575 |
12:50 ET | 813 | 0.3574 |
12:55 ET | 1025 | 0.35425 |
12:57 ET | 300 | 0.3574 |
01:00 ET | 100 | 0.3574 |
01:04 ET | 197 | 0.3574 |
01:08 ET | 100 | 0.3574 |
01:18 ET | 1015 | 0.3574 |
01:22 ET | 400 | 0.355821 |
01:26 ET | 1303 | 0.3559 |
01:27 ET | 800 | 0.3559 |
01:33 ET | 551 | 0.3575 |
01:36 ET | 275 | 0.3575 |
01:38 ET | 365 | 0.3544 |
01:40 ET | 200 | 0.3574 |
01:44 ET | 782 | 0.3575 |
01:45 ET | 100 | 0.3544 |
01:51 ET | 100 | 0.3575 |
02:05 ET | 289 | 0.3575 |
02:07 ET | 9697 | 0.36 |
02:09 ET | 5378 | 0.3639 |
02:12 ET | 1800 | 0.3592 |
02:18 ET | 175 | 0.36215 |
02:21 ET | 100 | 0.3625 |
02:23 ET | 300 | 0.3609 |
02:25 ET | 100 | 0.3625 |
02:27 ET | 100 | 0.365 |
02:36 ET | 2700 | 0.3602 |
02:38 ET | 100 | 0.365 |
02:41 ET | 136 | 0.365 |
02:43 ET | 2700 | 0.3603 |
02:52 ET | 100 | 0.365 |
02:56 ET | 200 | 0.365 |
02:57 ET | 100 | 0.365 |
03:01 ET | 377 | 0.3602 |
03:06 ET | 300 | 0.3626 |
03:12 ET | 100 | 0.365 |
03:14 ET | 425 | 0.3649 |
03:17 ET | 3275 | 0.362365 |
03:19 ET | 200 | 0.3622 |
03:21 ET | 1400 | 0.3619 |
03:24 ET | 580 | 0.3622 |
03:26 ET | 150 | 0.3622 |
03:28 ET | 100 | 0.3622 |
03:30 ET | 650 | 0.361 |
03:32 ET | 500 | 0.361 |
03:33 ET | 6255 | 0.3611 |
03:35 ET | 500 | 0.3549 |
03:37 ET | 2600 | 0.3622 |
03:48 ET | 500 | 0.3585 |
03:51 ET | 200 | 0.3621 |
04:00 ET | 1274 | 0.356 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
IGC Pharma Inc | 27.6M | -1.9x | --- |
Longeveron Inc | 28.0M | -0.3x | --- |
Pluri Inc | 27.2M | -1.2x | --- |
SAB Biotherapeutics Inc | 28.9M | -0.5x | --- |
GeoVax Labs Inc | 27.8M | -0.3x | --- |
Clene Inc. | 31.6M | -0.7x | --- |
IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $27.6M |
---|---|
Revenue (TTM) | $1.2M |
Shares Outstanding | 77.4M |
IGC Pharma Inc does not pay a dividend. | |
Beta | 1.29 |
EPS | $-0.19 |
Book Value | $0.11 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 23.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,070.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.